Earnings ·
Champions Oncology reported first-quarter fiscal 2027 results ending July 31, 2026
CSBRChampions Oncology, Inc.
Champions Oncology reported first-quarter fiscal 2027 results ending July 31, 2026. Revenue increased 8.8% year-over-year to $15.2 million, driven by higher core research services and data license revenue. The oncology services margin improved significantly to 51% from 43% in the prior-year period, while Adjusted EBITDA rose to $671,000 from $59,000. The company reported a net loss of $426,000 compared to a $466,000 loss previously. Operating expenses increased by 7.7% to $15.6 million due to investments in the commercial organization and R&D. Cash and cash equivalents stood at approximately $4.4 million with no debt. Champions Oncology operates as a global preclinical and clinical research services provider specializing in oncology drug discovery.